Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Member of the Roche Groupe, Spark Therapeutics, announced their updated data to challenge the inevitability of genetic disease.

Article from Spark Therapeutics